TOTsutomu Ohta

Tsutomu Ohta

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Tsutomu Ohta has a total of 21 co-authors. Here are the top co-authors by number of shared publications:

  • Mamiko Miyamoto

    Department of Innovative Seeds Evaluation, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan

    3 shared publications
  • Toshiki Watanabe

    Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan

    2 shared publications
  • Yuki Yamamoto

    Department of Innovative Seeds Evaluation, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan

    2 shared publications
  • Daisuke Tatsuda

    Authors' Affiliations: Division of Integrative Omics and Bioinformatics, National Cancer Center Research Institute; Institute of Microbial Chemistry (BIKAKEN), Tokyo; and

    1 shared publication
  • Hiroshi Mizushima

    Department of Computational Biology, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8510, Japan

    1 shared publication
  • Hiroshi Tanaka

    Department of Computational Biology, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8510, Japan

    1 shared publication

Latest Publications

  • Open Access

    Synovial sarcoma cell lines showed reduced DNA repair activity and sensitivity to a PARP inhibitor

    by Hiroyuki Yamasaki, Mamiko Miyamoto, Yuki Yamamoto, Tadashi Kondo, Toshiki Watanabe, Tsutomu Ohta

    Synovial sarcoma is a soft‐tissue sarcoma and a rare type of cancer. Unfortunately, effective chemotherapies for synovial sarcomas have not been established. In this report, we show that synovial sarcoma cell lines have reduced repair activity for DNA damage induced by ionizing radiation (IR) and a topoisomerase II inhibitor (etoposide). We also observed reduced recruitment of RAD51 homologue (S. cerevisiae; RAD51) at sites of double‐strand breaks (DSBs) in synovial sarcoma cell lines that had been exposed to IR. These findings showed that synovial sarcoma cell lines are defective in homologous recombination (HR) repair. Furthermore, we found that a poly‐(ADP‐ribose) polymerase (PARP) inhibitor (AZD2281; olaparib) effectively reduced the growth of synovial sarcoma cell lines in the presence of an alkylating agent (temozolomide). Our findings offer evidence that treatment combining a PARP inhibitor and an alkylating agent could have therapeutic benefits in the treatment of synovial sarcoma.


  • Open Access

    A Rare Polymorphic Variant of NBS1 Reduces DNA Repair Activity and Elevates Chromosomal Instability

    by Yuki Yamamoto, Mamiko Miyamoto, Daisuke Tatsuda, Michiaki Kubo, Hitoshi Nakagama, Yusuke Nakamura, Hitoshi Satoh, Koichi Matsuda, Toshiki Watanabe, Tsutomu Ohta

    Failure to expeditiously repair DNA at sites of double-strand breaks (DSB) ultimately is an important etiologic factor in cancer development. NBS1 plays an important role in the cellular response to DSB damage. A rare polymorphic variant of NBS1 that resulted in an isoleucine to valine substitution at amino acid position 171 (I171V) was first identified in childhood acute lymphoblastic leukemia. This polymorphic variant is located in the N-terminal region that interacts with other DNA repair factors. In earlier work, we had identified a remarkable number of structural chromosomal aberrations in a patient with pediatric aplastic anemia with a homozygous polymorphic variant of NBS1-I171V; however, it was unclear whether this variant affected DSB repair activity or chromosomal instability. In this report, we demonstrate that NBS1-I171V reduces DSB repair activity through a loss of association with the DNA repair factor MDC1. Furthermore, we found that heterozygosity in this polymorphic variant was associated with breast cancer risk. Finally, we showed that this variant exerted a dominant-negative effect on wild-type NBS1, attenuating DSB repair efficiency and elevating chromosomal instability. Our findings offer evidence that the failure of DNA repair leading to chromosomal instability has a causal impact on the risk of breast cancer development. Cancer Res; 74(14); 3707–15. ©2014 AACR.


  • Open Access

    Up‐regulation of PSF1 promotes the growth of breast cancer cells

    by Izumi Nakahara, Mamiko Miyamoto, Tatsuhiro Shibata, Sadako Akashi‐Tanaka, Takayuki Kinoshita, Kaoru Mogushi, Kohtaro Oda, Masaya Ueno, Nobuyuki Takakura, Hiroshi Mizushima, et al.

    PSF1 is a subunit of the GINS complex that functions along with the MCM2‐7 complex and Cdc45 in eukaryotic DNA replication. Although mammalian PSF1 is predominantly expressed in highly proliferating cells and organs, little is known about the roles of PSF1 in mature cells or cancer cells. We found that PSF1 was expressed at relatively high levels in breast tumor cells, but at low levels in normal breast cells. Knockdown of PSF1 expression using small interfering RNA (siRNA) slowed the growth of breast cancer cell lines by delaying DNA replication but did not affect proliferation of normal human mammary epithelial cells. Reduced PSF1 expression also inhibited anchorage‐independent growth in breast cancer cell lines. These results suggest that PSF1 over‐expression is specifically involved in breast cancer cell growth. Therefore, PSF1 inhibition might provide new therapeutic approaches for breast cancer.